

Date Shipment Needed: _____ Ship To: Patient Prescriber
 Nursing needed; Training needed ► All the supplies including syringes and needles will be dispensed if needed.

STARTER DOSE PAGE 1 **GASTROENTEROLOGY HUMIRA BIOSIMILAR REFERRAL FORM** **MAINTENANCE DOSE PAGE 2**

PATIENT INFORMATION
 Patient Name: _____ DOB: _____ Sex: M F Other: _____ Weight: _____ lbs. kg.
 SSN: _____ Phone: _____ Allergies: _____
 Address: _____ City: _____ State: _____ Zip: _____
 Emergency Contact: _____ Phone: _____ **Additional Information Attached**

PRESCRIBER INFORMATION
 Prescriber: _____ NPI: _____ DEA: _____ State Lic: _____
 Supervising Physician: _____ Practice Name: _____
 Address: _____ City: _____ State: _____ Zip: _____
 Phone: _____ Fax: _____ Key Office Contact: _____ Phone: _____

DIAGNOSIS INFORMATION / MEDICAL ASSESSMENT
Primary Diagnosis: (ICD-10 Code & Description) K50.00 K50.10 K50.80 K50.90 Crohn's Disease K51.9 Ulcerative Colitis Other: _____
 • Has patient been treated *previously* for this condition? Yes No Is patient *currently* on therapy? Yes No Please list medication(s) and treatment duration: _____
 • Will patient stop taking the above medication(s) before starting the new medication? Yes No If yes, how long should patient wait before starting the new medication? _____
 • Other medications patient is currently taking including OTC medications with dosage and direction (or fax medication profile): _____
 • Has patient received a **Quatiferon gold**, **Tspot** or **PPD (tuberculosis) Skin Test**? Yes No Date: _____ Results: Negative Positive

INSURANCE INFORMATION
 Please attach front and back of patient's insurance card (medical and prescription)

COPY CARD ENROLLMENT
 Please check if enrolling in copay card Copay ID: _____

PRESCRIPTION INFORMATION
Humira® CF **Starter Package 80 mg/0.8 mL Pen NDC: 0074-0124-03** Starter Dose Not Needed **Enroll in Humira Complete Program**
 Starter Dose: Two 80 mg SQ inj. **Day 1**, one 80 mg SQ inj. **Day 15** QTY: 3 Pens | Refills: 0
 Starter Dose: One 80 mg SQ inj. **Day 1**, one 80 mg SQ inj. **Day 2**, one 80 mg SQ inj. **Day 15** QTY: 3 Pens | Refills: 0
Humira® CF **40 mg/0.4 mL Pen NDC: 0074-0554-02** OR **40 mg/0.4 mL Prefilled Syringe NDC: 0074-0243-02**
 Maintenance Dose: One 40 mg SQ inj. **Day 29** & every other week thereafter QTY: 2 | Refills: _____
 Alternate Dose: _____ QTY: _____ | Refills: _____

Starter Dose (please make a selection) **No Starter Dose Needed - Select here if patient only needs maintenance dose**

Abrilada™ (adalimumab-afzb) <input type="checkbox"/> 40 mg/0.8 mL PFS <input type="checkbox"/> 40 mg/0.8 mL Pen	Amjevita® (adalimumab-atto) <input type="checkbox"/> 40 mg/0.8 mL PFS <input type="checkbox"/> 40 mg/0.8 mL Pen <input type="checkbox"/> 40 mg/0.4 mL PFS <input type="checkbox"/> 40 mg/0.4 mL Pen <input type="checkbox"/> 80 mg/0.8 mL Pen	Cyltezo® (adalimumab-adbm) <input type="checkbox"/> 40 mg/0.8 mL PFS <input type="checkbox"/> 40 mg/0.8 mL Pen <input type="checkbox"/> 40 mg/0.4 mL PFS <input type="checkbox"/> 40 mg/0.4 mL Pen <input type="checkbox"/> 40 mg/0.8 mL x 6 Pen CD/UC/HS Starter Kit	Hadlima® (adalimumab-bwwd) <input type="checkbox"/> 40 mg/0.8 mL PFS <input type="checkbox"/> 40 mg/0.8 mL Pen <input type="checkbox"/> 40 mg/0.4 mL PFS <input type="checkbox"/> 40 mg/0.4 mL Pen	Hulio® (adalimumab-fkjp) <input type="checkbox"/> 40 mg/0.8 mL PFS <input type="checkbox"/> 40 mg/0.8 mL Pen
Hyrimoz® (adalimumab-adaz) <input type="checkbox"/> 40 mg/0.4 mL PFS <input type="checkbox"/> 40 mg/0.4 mL Pen <input type="checkbox"/> 80 mg/0.8 mL Pen <input type="checkbox"/> 80 mg/0.8 mL x 3 Pen CD/UC Starter Kit <input type="checkbox"/> 80 mg/0.8 mL x 3 PFS CD Starter Kit (PEDS) <input type="checkbox"/> 80 mg/0.8 mL x 1 and 40 mg/0.4 mL x 1 PFS CD Starter Kit (PEDS)	Idacio® (adalimumab-aacf) <input type="checkbox"/> 40 mg/0.8 mL PFS <input type="checkbox"/> 40 mg/0.8 mL Pen <input type="checkbox"/> 40 mg/0.8 mL x 6 Pen CD/UC Starter Kit	Simlandi® (adalimumab-ryvk) <input type="checkbox"/> 40 mg/0.4 mL PFS <input type="checkbox"/> 40 mg/0.4 mL Pen	Yuflyma® (adalimumab-aaty) <input type="checkbox"/> 40 mg/0.4 mL PFS <input type="checkbox"/> 40 mg/0.4 mL Pen <input type="checkbox"/> 80 mg/0.8 mL Pen <input type="checkbox"/> 80 mg/0.8 mL x 3 Pen CD/UC/HS Starter Kit	Yusimry® (adalimumab-aqvh) <input type="checkbox"/> 40 mg/0.8 mL Pen

Directions (please select one)	QUANTITY	REFILLS
<input type="checkbox"/> Inj 160 mg SQ Day 1, then 80 mg SQ Day 15	28 DAY SUPPLY	0
<input type="checkbox"/> (for CD, PEDS ≥ 6yo, 17 kg to <40 kg) Inj 80 mg SQ Day 1, then 40 mg SQ Day 15 DO NOT SELECT this PEDS Starter Dosing with Hadlima, Idacio, Simlandi, Yuflyma or Yusimry (due to no 20 mg dosing available for Maintenance)	28 DAY SUPPLY	0
<input type="checkbox"/> Other:		0

Please select Maintenance Dose below (see page 2)

Prescriber's Signature: _____ DAW (Dispense as Written) **Date:** _____

Prescriber certifies that this referral form contains an original signature and is signed by the treating prescriber. NO STAMPED SIGNATURES WILL BE ACCEPTED. Where required by law, send electronic prescription or on official state prescription blank. In the event requested agent is not available through AcariaHealth, this prescription shall be forwarded to an eligible pharmacy.

IMPORTANT NOTICE: This message may contain privileged and confidential information and is intended only for the individual named. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please notify the sender immediately if you have received this document by mistake, then destroy this document. Please direct all verification or notification to AcariaHealth or any of its subsidiaries using the contact information provided on this coversheet.

Date Shipment Needed: _____ Ship To: Patient Prescriber
 Nursing needed; Training needed ► All the supplies including syringes and needles will be dispensed if needed.

STARTER DOSE PAGE 1

GASTROENTEROLOGY HUMIRA BIOSIMILAR REFERRAL FORM

MAINTENANCE DOSE PAGE 2

PATIENT INFORMATION

Patient Name: _____ DOB: _____ Sex: M F Other: _____ Weight: _____ lbs. kg.
 SSN: _____ Phone: _____ Allergies: _____
 Address: _____ City: _____ State: _____ Zip: _____
 Emergency Contact: _____ Phone: _____ **Additional Information Attached**

PRESCRIBER INFORMATION

Prescriber: _____ NPI: _____ DEA: _____ State Lic: _____
 Supervising Physician: _____ Practice Name: _____
 Address: _____ City: _____ State: _____ Zip: _____
 Phone: _____ Fax: _____ Key Office Contact: _____ Phone: _____

DIAGNOSIS INFORMATION / MEDICAL ASSESSMENT

Primary Diagnosis: (ICD-10 Code & Description) K50.00 K50.10 K50.80 K50.90 Crohn's Disease K51.9 Ulcerative Colitis Other: _____
 • Has patient been treated *previously* for this condition? Yes No Is patient *currently* on therapy? Yes No Please list medication(s) and treatment duration: _____
 • Will patient stop taking the above medication(s) before starting the new medication? Yes No If yes, how long should patient wait before starting the new medication? _____
 • Other medications patient is currently taking including OTC medications with dosage and direction (or fax medication profile): _____
 • Has patient received a **Quatiferon gold, Tspot or PPD (tuberculosis) Skin Test?** Yes No Date: _____ Results: Negative Positive

INSURANCE INFORMATION

Please attach front and back of patient's insurance card (medical and prescription)

COPAY CARD ENROLLMENT

Please check if enrolling in copay card Copay ID: _____

PRESCRIPTION INFORMATION

Maintenance Dose (please make a selection)

<p>Abrilada™ (adalimumab-afzb)</p> <input type="checkbox"/> 20 mg/0.4 mL PFS <input type="checkbox"/> 40 mg/0.8 mL PFS <input type="checkbox"/> 40 mg/0.8 mL Pen	<p>Amjevita® (adalimumab-atto)</p> <input type="checkbox"/> 20 mg/0.2 mL PFS <input type="checkbox"/> 20 mg/0.4 mL PFS <input type="checkbox"/> 40 mg/0.8 mL PFS <input type="checkbox"/> 40 mg/0.8 mL Pen <input type="checkbox"/> 40 mg/0.4 mL PFS <input type="checkbox"/> 40 mg/0.4 mL Pen	<p>Cyltezo® (adalimumab-adbm)</p> <input type="checkbox"/> 20 mg/0.4 mL PFS <input type="checkbox"/> 40 mg/0.8 mL PFS <input type="checkbox"/> 40 mg/0.8 mL Pen <input type="checkbox"/> 40 mg/0.4 mL PFS <input type="checkbox"/> 40 mg/0.4 mL Pen	<p>Hadlima® (adalimumab-bwwd)</p> <input type="checkbox"/> 40 mg/0.8 mL PFS <input type="checkbox"/> 40 mg/0.8 mL Pen <input type="checkbox"/> 40 mg/0.4 mL PFS <input type="checkbox"/> 40 mg/0.4 mL Pen	<p>Hulio® (adalimumab-rljp)</p> <input type="checkbox"/> 20 mg/0.4 mL PFS <input type="checkbox"/> 40 mg/0.8 mL PFS <input type="checkbox"/> 40 mg/0.8 mL Pen
<p>Hyrimoz® (adalimumab-adaz)</p> <input type="checkbox"/> 20 mg/0.2 mL PFS <input type="checkbox"/> 40 mg/0.4 mL PFS <input type="checkbox"/> 40 mg/0.4 mL Pen	<p>Idacio® (adalimumab-aacf)</p> <input type="checkbox"/> 40 mg/0.8 mL PFS <input type="checkbox"/> 40 mg/0.8 mL Pen	<p>Simlandi® (adalimumab-ryvk)</p> <input type="checkbox"/> 40 mg/0.4 mL PFS <input type="checkbox"/> 40 mg/0.4 mL Pen	<p>Yuflyma® (adalimumab-aaty)</p> <input type="checkbox"/> 40 mg/0.4 mL PFS <input type="checkbox"/> 40 mg/0.4 mL Pen	<p>Yusimry® (adalimumab-aqvh)</p> <input type="checkbox"/> 40 mg/0.8 mL Pen

Directions (please select one)	QUANTITY	REFILLS
<input type="checkbox"/> Inj 40 mg SQ every other week	28 DAY SUPPLY	
<input type="checkbox"/> (for CD, PEDS 17 kg to <40 kg) Inj 20 mg SQ every other week	28 DAY SUPPLY	
<input type="checkbox"/> Other:		

Prescriber's Signature: _____ DAW (Dispense as Written) **Date:** _____

Prescriber certifies that this referral form contains an original signature and is signed by the treating prescriber. **NO STAMPED SIGNATURES WILL BE ACCEPTED.** Where required by law, send electronic prescription or on official state prescription blank. In the event requested agent is not available through AcariaHealth, this prescription shall be forwarded to an eligible pharmacy.

IMPORTANT NOTICE: This message may contain privileged and confidential information and is intended only for the individual named. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please notify the sender immediately if you have received this document by mistake, then destroy this document. Please direct all verification or notification to AcariaHealth or any of its subsidiaries using the contact information provided on this coversheet.